Clinical value of TV-CDS combined with serum tumor markers in diagnosis of ovarian cancer

被引:12
|
作者
Yu, Chunying [1 ]
Dou, Ting [1 ]
Liu, Yun [1 ]
Liu, Ruirong [1 ]
机构
[1] Third Peoples Hosp Qingdao, Dept Ultrason Med, 29 Yongping Rd, Qingdao 266041, Shandong, Peoples R China
关键词
ovarian cancer; color doppler ultrasound; transvaginal; tumor markers; serology; combined examination; DOPPLER SONOGRAPHY; OSTEOPONTIN; STAGE; DISCRIMINATION; ULTRASOUND; CA125;
D O I
10.3892/ol.2020.11705
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical application value was investigated of transvaginal color Doppler ultrasound (TV-CDS) combined with serum tumor markers carbohydrate antigen 125 (CA125), vascular endothelial growth factor (VEGF) and osteopontin (OPN) in the diagnosis of ovarian cancer (OC). One hundred and six patients with OC [malignant tumor group (MTG)] and fifty patients with benign ovarian diseases [benign control group (BCG)] were selected. Both groups of patients underwent TV-CDS examination. The lesion morphology and internal structure were observed, and the tumor blood flow signal, resistance index (RI) and pulsability index (PI) under ultrasound were determined. Serum CA125 was detected by electrochemiluminescence, and VEGF and OPN levels were detected by enzyme-linked immunosorbent assay. The incidence of irregular lesion morphology, unclear boundary, uneven internal echo, microcalcification and side-acoustic images in OC group (OCG) was significantly higher than that in BCG (P<0.01). As for blood flow grading, most patients in the MTG were in grade II and III, while most patients in the BCG were in grade 0. Compared with BCG, the flow RI and PI in the OCG were significantly reduced (P<0.01). The levels of serum CA125, VEGF and OPN in OCG were significantly higher than those in BCG. The expression levels of serum CA125, VEGF and OPN in OC patients with clinical high stage (stage III and IV), poorly differentiated, ascites, recurrence and metastasis were significantly higher than those in patients with clinical low stage (stage I and II), well differentiated, no ascites and no recurrence and metastasis (P<0.05). With the disappearance of the tumor or the decrease of tumor load, the serum marker levels after treatment were significantly lower than that before treatment (P<0.05). The sensitivity and accuracy of the combined examination in the diagnosis of OC were obviously improved compared with the single and partial combined examinations (P<0.05). In conclusion, combined examination can significantly improve the sensitivity and accuracy of OC, which is conducive to early diagnosis and clinical intervention of OC.
引用
收藏
页码:2028 / 2034
页数:7
相关论文
共 50 条
  • [41] Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer
    Song, Xiuqin
    Liang, Bo
    Wang, Chenghong
    Shi, Shan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (02) : 1822 - 1828
  • [42] Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer
    Xi, Q. -P.
    Pu, D. -H.
    Lu, W. -N.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (20) : 4536 - 4541
  • [43] Determining the Diagnostic Strength of Serum Tumor Markers in Epithelial Ovarian Cancer in Women from Lahore, Pakistan
    Hussain, Rizwana
    Khaliq, Saba
    Ahmad, Hafiz Usman
    ANNALS OF KING EDWARD MEDICAL UNIVERSITY LAHORE PAKISTAN, 2024, 30 (03): : 223 - 230
  • [44] Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer
    Li, Yang
    Tian, Xudong
    Gao, Lei
    Jiang, Xiaohong
    Fu, Rao
    Zhang, Tingting
    Ren, Tianying
    Hu, Ping
    Wu, Yaping
    Zhao, Peige
    Yang, Dawei
    CANCER MEDICINE, 2019, 8 (08): : 3782 - 3792
  • [45] CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
    Duffy, MJ
    Bonfrer, JM
    Kulpa, J
    Rustin, GJS
    Soletormos, G
    Torre, GC
    Tuxen, MK
    Zwirner, M
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) : 679 - 691
  • [46] Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors
    Santotoribio, J. D.
    Garcia-de la Torre, A.
    Canavate-Solano, C.
    Arce-Matute, F.
    Sanchez-del Pino, M. J.
    Perez-Ramos, S.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (01) : 26 - 29
  • [47] Clinical Value of Combined Multi-Indicator Tests in Diagnosis of Benign Ovarian
    Yang, Lunyun
    Du, Lin
    Hou, Bailong
    Niu, Xiaoqin
    Wang, Wei
    Shen, Weifeng
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 2047 - 2053
  • [48] The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer
    Hogdall, CK
    Norgaard-Pedersen, B
    Mogensen, O
    ANTICANCER RESEARCH, 2002, 22 (03) : 1765 - 1768
  • [49] CT combined with tumor markers in the diagnosis and prognosis of hepatocellular carcinoma
    Huang, Xingwen
    Li, Jianlin
    Wang, Fuzheng
    Hao, Mingda
    JOURNAL OF BUON, 2018, 23 (04): : 985 - 991
  • [50] Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer Updated Guidelines From the European Group on Tumor Markers
    Soletormos, Gyorgy
    Duffy, Michael J.
    Abu Hassan, Suher Othman
    Verheijen, Rene H. M.
    Tholander, Bengt
    Bast, Robert C., Jr.
    Gaarenstroom, Katja N.
    Sturgeon, Catharine M.
    Bonfrer, Johannes M.
    Petersen, Per Hyltoft
    Troonen, Hugo
    CarloTorre, Gian
    Kulpa, Jan Kanty
    Tuxen, Malgorzata K.
    Molina, Raphael
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (01) : 43 - 51